RegoNivo vs Standard of Care Chemotherapy in AGOC

NCT04879368 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

450

Enrollment

NETWORK

Sponsor class

Conditions

Gastro-Oesophageal Cancer

Interventions

DRUG: Regorafenib
BIOLOGICAL: Nivolumab
DRUG: Docetaxel
DRUG: Paclitaxel
DRUG: Irinotecan
DRUG: Trifluridine/Tipracil

Sponsor

Australasian Gastro-Intestinal Trials Group

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]